iRegene Therapeutics's NouvSight001 Cleared for Clinical Trials in the U.S. and China for Retinitis Pigmentosa
- Following its Parkinson's disease program, iRegene advances another off-the-shelf cell therapy into clinical development in the U.S. and China. CHENGDU, China, Sept. 29, 2026 /PRNewswire/ -- iRegene Therapeutics Co., Ltd. ("iRegene" or the...
Accro Bioscience Announces IND Clearance from NMPA for Phase II/III Clinical Trial of AC-201, a Highly Selective TYK2/JAK1 Inhibitor for the Treatment of Non-Segmental Vitiligo
NEW YORK and SUZHOU, China, Sept. 8, 2026 /PRNewswire/ -- Accro Bioscience (Suzhou) Limited ("Accro") today announced that Shanghai Fosun Pharmaceutical Industrial Development Company Limited ("Fosun Pharma Industrial"), a subsidiary of its partner...